hSCN9A(SD) Rat
製品名
hSCN9A(SD) Rat
製品ID
CR013
系統名
SD-Scn9aem1(hSCN9A)/Cya
背景情報
SD
状況
このマウス系統を論文で使用する場合は、「hSCN9A(SD) Rat（カタログ番号CR013）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
PN1, ETHA, NENA, SFNP, FEB3B, NE-NA, GEFSP7, HSAN2D, Nav1.7
NCBI ID
染色体
Chr 2
MGI ID
さらに
系統詳細
The SCN9A gene, which encodes the voltage-gated sodium channel protein Nav1.7, is an important pathogenic factor underlying peripheral neuropathic pain and related rare diseases. Nav1.7 sodium channels mediate the influx of positively charged sodium ions into cells and play a critical role in the generation and propagation of action potentials. Studies have shown that genetic variants in SCN9A are closely associated with multiple inherited pain disorders, including erythromelalgia, small fiber neuropathy, and congenital insensitivity to pain [1-2]. As a voltage-gated sodium channel, the Nav1.7 protein is predominantly expressed in sensory and sympathetic neurons of the peripheral nervous system, with particularly high expression in dorsal root ganglia, where it plays an essential role in the generation and transmission of pain signals [3]. Research indicates that down-regulation of SCN9A expression or selective inhibition of Nav1.7 holds promise as a novel and highly effective analgesic strategy for the treatment of acute, inflammatory, and neuropathic pain [4].
Currently, drug development targeting SCN9A/Nav1.7 continues to advance and encompasses multiple modalities, including small-molecule inhibitors, epigenetic regulation, gene therapy, and biologic agents. Several companies have established relevant pipelines; for example, raxatrigine from GSK has entered Phase III clinical trials for trigeminal neuralgia, while Xenon Pharmaceuticals, Vertex Pharmaceuticals, and others are actively progressing selective Nav1.7 inhibitors in preclinical and early clinical stages [5].
hSCN9A(SD) rat is a humanized Scn9a model generated by gene-editing technology. The coding sequence of exon 2 to partial intron 7 of rat Scn9a was replaced with the Kozak-Human SCN9A CDS-3'UTR of Human SCN9A-WPRE-BGH pA cassette. This model can be used for investigating the pathogenic mechanisms of inherited pain disorders such as erythromelalgia, small fiber neuropathy, and congenital insensitivity to pain, as well as for the preclinical research, screening, and evaluation of Nav1.7-targeted analgesic candidates.
参考文献
Ghanty I, Perez-Palma E, Villaman C, et al. SCN9A should not be considered an epilepsy gene; Refuting a gene-disease association. Epilepsia. 2025;66(9):3516-3527.
Gomez K, Stratton HJ, Duran P, et al. Identification and targeting of a unique NaV1.7 domain driving chronic pain. Proc Natl Acad Sci U S A. 2023;120(32):e2217800120.
Waxman SG. NaV1.7: A central role in pain. Neuron. 2023;111(17):2615-2617.
Sutemieva JA, Sobenin DV. Voltage-gated sodium channels in pain: Which channels, which blockers, and where NaV1.7 fits. Prog Biophys Mol Biol. 2026;200:138-162.
Xia P, Mo R, Hu L, Yang Y. Six at Sixty. 'No gain, no pain': medical genetics taking Nav1.7 from target to pharmacy. J Med Genet. 2025;62(10):654-657.
系統作製戦略
The coding sequence of exon 2 to partial intron 7 of rat Scn9a was replaced with the Kozak-Human SCN9A CDS-3'UTR of Human SCN9A-WPRE-BGH pA cassette.
Figure 1. Gene editing strategy of hSCN9A(SD) rats.
適用分野
Research on the pathogenic mechanisms of inherited pain disorders such as erythromelalgia, small nerve fiber neuropathy, and congenital insensitivity to pain;
Preclinical research, screening, and evaluation of Nav1.7-targeted analgesic candidates.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。